Medical Pharmacology: Chapter 18: Antiparkinson's Disease Drugs -- Module 6: Anticholinergics, Amantadine ER, and Adjunct Pharmacology

Chapter 18: Antiparkinson's Disease Drugs — Module 6: Anticholinergics, Amantadine ER, and Adjunct Pharmacology
Tier: T2

1. A 63-year-old man with Parkinson's disease (PD) on levodopa/carbidopa has two distinct motor problems: resting tremor that is incompletely controlled on his current regimen, and peak-dose choreiform dyskinesia that limits his ability to perform fine motor tasks. He has intact cognition, no BPH, and no glaucoma. His neurologist considers adding either trihexyphenidyl or amantadine extended-release (ER). Which of the following best explains why each agent is appropriate for one problem but not the other, and what the correct prescribing decision is?

A) Trihexyphenidyl is appropriate for both tremor and dyskinesia because muscarinic M1 blockade in the striatum reduces both cholinergic-mediated tremor and the corticostriatal glutamatergic drive that generates dyskinesia; amantadine ER is redundant in this patient.
B) Amantadine ER is appropriate for both tremor and dyskinesia because NMDA antagonism reduces pathological glutamatergic signaling that underlies both motor symptoms; trihexyphenidyl adds anticholinergic adverse effect burden without additional motor benefit in this patient.
C) Both agents should be added simultaneously — trihexyphenidyl for tremor and amantadine ER for dyskinesia — because their mechanisms are entirely complementary with no overlapping adverse effects and no reason to sequence one before the other.
D) Trihexyphenidyl targets the cholinergic excess that contributes to tremor through muscarinic blockade but has no antidyskinetic mechanism; amantadine ER targets the pathological glutamatergic drive that underlies dyskinesia through NMDA antagonism but is not a primary tremor agent — since dyskinesia is the more functionally limiting problem in this patient, amantadine ER is the correct single agent to add first, with trihexyphenidyl reconsidered only if tremor remains the dominant complaint after dyskinesia is controlled.
E) Neither agent is appropriate because the patient has two competing motor problems that require dopaminergic rebalancing rather than adjunct pharmacotherapy; the correct intervention is to split the levodopa dose into smaller more frequent doses before adding any non-dopaminergic agent.

ANSWER: D

Rationale:

This question requires precise mechanism discrimination between two agents with entirely different pharmacological targets. Trihexyphenidyl is a muscarinic M1 receptor antagonist that corrects the relative cholinergic excess in the striatum produced by dopamine depletion; its primary clinical benefit is tremor suppression, and it has no established antidyskinetic mechanism — muscarinic blockade does not attenuate the corticostriatal glutamatergic signaling that underlies peak-dose dyskinesia. Amantadine ER is an uncompetitive NMDA receptor antagonist that reduces the pathologically elevated glutamatergic drive implicated in dyskinesia genesis; it carries the specific FDA indication for levodopa-induced dyskinesia and holds the EASE LID trial evidence base. While amantadine ER has modest dopaminergic effects, it is not a primary tremor agent and is not positioned as such. When a patient has both problems, the correct approach is to identify which is more functionally limiting and address that first with the mechanistically appropriate agent. In this patient, dyskinesia limiting fine motor tasks is the dominant functional problem, making amantadine ER the correct first addition. Trihexyphenidyl can be reconsidered as a second agent for residual tremor if indicated, provided contraindications remain absent. Option D correctly applies this prioritization logic.

Option A: Option A is incorrect; trihexyphenidyl has no established antidyskinetic mechanism — muscarinic blockade does not reduce the glutamatergic component of dyskinesia.
Option B: Option B is incorrect; amantadine ER's NMDA antagonism does not target the cholinergic excess that mediates tremor — its tremor benefit, if any, is modest and not the basis for its clinical use.
Option C: Option C is incorrect; while simultaneous addition is not pharmacologically impossible, the clinical rationale for sequencing — identifying the dominant problem and targeting it first — is the appropriate approach, and the assertion that there are no overlapping adverse effects is incorrect since both agents can cause hallucinations.
Option E: Option E is incorrect; levodopa dose splitting is a strategy for wearing-off, not for dyskinesia — splitting doses into smaller more frequent administrations can worsen dyskinesia by increasing the frequency of peak-dose exposure.

2. A pharmacist contacts a neurologist to clarify an amantadine extended-release (ER) prescription for a patient with Parkinson's disease (PD) and levodopa-induced dyskinesia. The prescription reads "amantadine ER 129 mg once daily in the morning." The pharmacist notes that there are two approved amantadine ER formulations — Gocovri and Osmolex ER — and asks whether the prescriber intended to treat dyskinesia or PD motor symptoms. Which of the following best explains the clinically important distinction between these two formulations?

A) Gocovri (amantadine ER 137 mg at bedtime) is the only amantadine ER formulation with an FDA indication specifically for levodopa-induced dyskinesia, supported by the EASE LID trial program; Osmolex ER (amantadine ER 129 mg in the morning) is approved for PD motor symptoms and drug-induced extrapyramidal reactions but does not carry the dyskinesia indication — for a patient whose primary problem is dyskinesia, Gocovri at bedtime is the pharmacokinetically and clinically appropriate choice.
B) The two formulations are therapeutically interchangeable for dyskinesia because both contain extended-release amantadine; the difference in dosing time is a manufacturer preference rather than a pharmacokinetically meaningful distinction, and either can be substituted at an equivalent milligram dose.
C) Osmolex ER 129 mg in the morning is preferred over Gocovri for dyskinesia because morning dosing aligns peak amantadine concentrations with the afternoon period when levodopa-induced dyskinesia is most severe in most patients, making it pharmacokinetically superior to bedtime dosing.
D) Both Gocovri and Osmolex ER carry identical FDA indications for levodopa-induced dyskinesia; the distinction is solely in release rate — Gocovri produces a faster initial release suited to acute dyskinesia episodes while Osmolex ER produces a slower sustained release suited to chronic dyskinesia management.
E) Gocovri is approved only for wearing-off management and off-time reduction in levodopa-treated patients; Osmolex ER is the correct formulation for dyskinesia because its morning dosing produces peak concentrations during peak-dose dyskinesia periods in the afternoon.

ANSWER: A

Rationale:

There are two FDA-approved extended-release amantadine formulations that differ in dose, dosing time, release profile, and approved indications. Gocovri (amantadine ER 137 mg) is taken once daily at bedtime; the extended-release formulation produces peak plasma concentrations during the morning hours, aligning maximal NMDA receptor antagonism with the period when levodopa-induced dyskinesia and off-periods are typically most severe. Gocovri received FDA approval in 2017 specifically for the treatment of dyskinesia in patients with PD receiving levodopa-based regimens — a first-in-class indication — based on the EASE LID and EASE LID 3 trial data. Osmolex ER (amantadine ER 129 mg) is taken once daily in the morning and was approved in 2018 for PD motor symptoms and drug-induced extrapyramidal reactions, but it does not carry the specific dyskinesia indication that Gocovri holds. The two formulations are not interchangeable for the dyskinesia indication, and prescribing Osmolex ER for a patient whose clinical problem is dyskinesia would be using an off-label formulation when an on-label one exists. The prescription for "amantadine ER 129 mg in the morning" describes Osmolex ER — not the indicated formulation for this patient — and should be clarified. Option A correctly distinguishes the two formulations by indication and dosing rationale.

Option B: Option B is incorrect; the formulations are not therapeutically interchangeable for dyskinesia — the dosing time difference reflects a deliberate pharmacokinetic design that aligns peak concentrations with the morning period of greatest dyskinesia burden, and the indications differ.
Option C: Option C is incorrect; it inverts the pharmacokinetic rationale — bedtime dosing of Gocovri produces morning peak concentrations, which is the pharmacokinetically appropriate timing for dyskinesia; morning dosing of Osmolex ER does not replicate this profile.
Option D: Option D is incorrect; the indications are not identical — only Gocovri carries the specific dyskinesia indication, and the characterization of release-rate differences as distinguishing acute from chronic use is fabricated.
Option E: Option E is incorrect; Gocovri is indicated for dyskinesia, not for wearing-off or off-time reduction — those are secondary benefits, not the approved indication; this option reverses the indications of the two formulations.

3. A 74-year-old man with Parkinson's disease (PD) is brought to the emergency department with agitated delirium, hyperthermia, tachycardia, urinary retention, and absent bowel sounds following inadvertent dose escalation of his trihexyphenidyl. The emergency physician considers physostigmine. Which of the following best explains the mechanistic rationale for physostigmine in this setting, and what property distinguishes it from other cholinesterase inhibitors?

A) Physostigmine is a nicotinic receptor agonist that directly reverses the peripheral muscarinic blockade of trihexyphenidyl by competing for the same binding site on M1 receptors in the striatum and M3 receptors in peripheral smooth muscle.
B) Physostigmine inhibits acetylcholinesterase at the neuromuscular junction, increasing acetylcholine (ACh) concentrations at nicotinic receptors and restoring neuromuscular transmission impaired by the anticholinergic-induced peripheral neuropathy.
C) Physostigmine is a reversible acetylcholinesterase inhibitor that crosses the blood-brain barrier (BBB) — unlike quaternary cholinesterase inhibitors such as neostigmine and pyridostigmine — allowing it to increase ACh concentrations at both central and peripheral muscarinic receptors, thereby pharmacologically reversing both the delirium and peripheral manifestations of anticholinergic toxicity.
D) Physostigmine competitively antagonizes trihexyphenidyl at the muscarinic M1 receptor, displacing it from the receptor and directly restoring cholinergic tone; its BBB penetrance allows this competitive displacement to occur in both central and peripheral compartments simultaneously.
E) Physostigmine increases synaptic ACh by blocking the vesicular ACh transporter (VAChT), preventing ACh reuptake into presynaptic terminals and thereby prolonging its availability at muscarinic receptors blocked by trihexyphenidyl.

ANSWER: C

Rationale:

Physostigmine is a reversible inhibitor of acetylcholinesterase — the enzyme that degrades acetylcholine (ACh) in the synaptic cleft. By inhibiting this enzyme, physostigmine increases the concentration and dwell time of ACh at muscarinic and nicotinic receptors, allowing endogenous ACh to compete more effectively with and partially overcome the muscarinic receptor blockade produced by anticholinergic agents such as trihexyphenidyl. The critical property that makes physostigmine specifically useful for central anticholinergic toxicity — and distinguishes it from other cholinesterase inhibitors — is its ability to cross the blood-brain barrier (BBB). Physostigmine is a tertiary amine that is lipid-soluble and penetrates the CNS; quaternary ammonium compounds such as neostigmine and pyridostigmine carry a permanent positive charge that prevents BBB penetration, confining their cholinesterase inhibition to the periphery. Because central anticholinergic toxicity (delirium, hallucinations, agitation) is the most dangerous and least reversible component of the toxidrome, an agent that restores central cholinergic tone is required. Option C correctly identifies physostigmine as a reversible acetylcholinesterase inhibitor with BBB penetrance, distinguishing it from quaternary cholinesterase inhibitors.

Option A: Option A is incorrect; physostigmine is not a nicotinic receptor agonist and does not directly compete with trihexyphenidyl at muscarinic receptor binding sites — it acts by increasing ACh concentrations indirectly through enzyme inhibition.
Option B: Option B is incorrect; physostigmine's relevant mechanism in anticholinergic toxicity is at muscarinic receptors, not nicotinic receptors at the neuromuscular junction, and anticholinergic agents do not cause peripheral neuropathy.
Option D: Option D is incorrect; physostigmine does not competitively displace trihexyphenidyl from muscarinic receptors — it is an acetylcholinesterase inhibitor, not a receptor-level competitive antagonist; the distinction between enzyme inhibition and receptor competition is pharmacologically fundamental.
Option E: Option E is incorrect; physostigmine inhibits acetylcholinesterase in the synaptic cleft, not the vesicular ACh transporter — VAChT is a presynaptic storage mechanism, not a reuptake transporter, and its inhibition is not the mechanism of any clinically used cholinesterase inhibitor.

4. Amantadine has both NMDA receptor antagonist and dopaminergic properties. A pharmacology resident asks why amantadine's dopaminergic mechanism was clinically prominent in early reports of the drug's antiparkinson effect in the 1960s, but is now considered less relevant in the current context of amantadine extended-release (ER) use in advanced Parkinson's disease (PD). Which of the following best explains this shift in the clinically dominant mechanism across disease stages?

A) Amantadine's dopaminergic effect has been superseded because newer formulations of amantadine ER have eliminated the dopamine-releasing component through targeted pharmacokinetic modification of the release matrix, retaining only the NMDA antagonist fraction of the drug.
B) Amantadine's dopaminergic effect was always a misattribution; early reports of antiparkinson benefit were entirely due to NMDA antagonism, and the historical belief in a dopaminergic component reflects inadequate trial methodology in the 1960s rather than genuine pharmacology.
C) Amantadine's dopaminergic properties were dominant early because NMDA receptor antagonism requires prolonged receptor adaptation before producing clinical benefit; the extended-release formulation provides a long enough exposure window for NMDA-mediated plasticity to accumulate.
D) Amantadine's dopaminergic mechanism remains the clinically dominant effect at all stages of PD; the framing of amantadine ER as primarily an NMDA antagonist for dyskinesia is a regulatory artifact of the EASE LID trial design rather than a pharmacological reality.
E) In early PD, surviving nigrostriatal terminals are present in sufficient number for amantadine's dopamine-releasing and reuptake-inhibiting effects to produce meaningful symptomatic benefit; in advanced PD, progressive nigrostriatal degeneration has eliminated most of the presynaptic terminals on which the dopaminergic mechanism depends, leaving NMDA antagonism as the clinically dominant mechanism — which is why the dyskinesia indication, not dopaminergic augmentation, defines amantadine ER's current clinical role.

ANSWER: E

Rationale:

Amantadine has multiple pharmacological actions that include promoting dopamine release from presynaptic terminals, inhibiting dopamine reuptake, and weak MAO inhibitory activity — in addition to its better-characterized uncompetitive NMDA receptor antagonism. In early PD, when a substantial number of nigrostriatal dopaminergic terminals remain intact, these presynaptic dopaminergic mechanisms can produce clinically meaningful increases in synaptic dopamine. Early case reports and open-label observations from the 1960s correctly attributed some of amantadine's antiparkinson benefit to dopaminergic augmentation from a partially intact nigrostriatal system. As PD advances, however, progressive neurodegeneration destroys the majority of nigrostriatal terminals; with few or no presynaptic terminals remaining, the dopamine-releasing and reuptake-inhibiting actions of amantadine lose their substrate and become pharmacologically inert. In this context, NMDA receptor antagonism — which operates postsynaptically at corticostriatal synapses independent of the dopaminergic system — becomes the dominant and clinically actionable mechanism. This is the pharmacological basis for why amantadine ER's approved clinical role in advanced PD centers on dyskinesia management through NMDA antagonism rather than dopaminergic augmentation. Option E correctly explains this disease-stage-dependent shift in dominant mechanism.

Option A: Option A is incorrect; the dopaminergic properties of amantadine have not been pharmacokinetically engineered out of the extended-release formulation — both formulations contain the same amantadine molecule with identical pharmacological actions.
Option B: Option B is incorrect; amantadine does have genuine dopaminergic properties confirmed in multiple experimental and clinical studies; dismissing the dopaminergic component as a methodological artifact is pharmacologically inaccurate.
Option C: Option C is incorrect; NMDA receptor antagonism does not require prolonged receptor adaptation to produce its antidyskinetic effect — the mechanism is not mediated by receptor plasticity but by acute reduction of glutamatergic drive at NMDA receptors.
Option D: Option D is incorrect; the NMDA antagonist mechanism is pharmacologically genuine and not a regulatory artifact — the EASE LID trials measured a real pharmacodynamic effect of NMDA blockade on dyskinesia, and the dopaminergic mechanism does not remain clinically dominant across all disease stages as this option claims.

5. Adenosine A2A receptors and dopamine D2 receptors are co-expressed on striatopallidal medium spiny neurons of the indirect pathway and function as functional antagonists — activation of one opposes signaling through the other. A neurologist is adding istradefylline to the regimen of a patient with Parkinson's disease (PD) who is already on pramipexole (a D2/D3 agonist) and levodopa/carbidopa. Which of the following best describes the mechanistic interaction between istradefylline's A2A blockade and pramipexole's D2/D3 agonism on striatopallidal neurons, and its clinical implication?

A) Istradefylline and pramipexole are pharmacologically redundant on striatopallidal neurons because both reduce indirect pathway activity; co-administration produces no additive effect and istradefylline should not be prescribed in patients already receiving a dopamine agonist.
B) By blocking A2A receptors on striatopallidal neurons, istradefylline removes the adenosinergic opposition to D2 receptor signaling, effectively potentiating pramipexole's D2-mediated suppression of striatopallidal neuron firing; this synergistic indirect pathway inhibition can produce additive motor benefit but also raises the risk of additive dopaminergic adverse effects including dyskinesia, hallucinations, and impulse control disorders that must be monitored when the two agents are co-prescribed.
C) Istradefylline's A2A blockade upregulates D2 receptor expression on striatopallidal neurons through a compensatory mechanism, increasing pramipexole's binding affinity and requiring pramipexole dose reduction by approximately 25 percent to maintain equivalent D2 receptor occupancy.
D) Pramipexole's D2 agonism downregulates A2A receptor expression on striatopallidal neurons, reducing the pharmacodynamic target for istradefylline and making A2A blockade less effective in patients already on dopamine agonists; istradefylline should therefore be reserved for patients not receiving dopamine agonists.
E) The A2A and D2 receptors on striatopallidal neurons signal through entirely separate intracellular pathways with no cross-regulation; istradefylline's A2A blockade and pramipexole's D2 agonism produce purely additive, non-interacting effects on motor output with no implication for adverse effect monitoring beyond what each drug produces individually.

ANSWER: B

Rationale:

The A2A and D2 receptors on striatopallidal medium spiny neurons form a well-characterized receptor heteromer system in which the two receptors functionally antagonize each other at the intracellular signaling level — A2A receptor activation increases cAMP and promotes striatopallidal neuron firing, while D2 receptor activation decreases cAMP and inhibits firing. When istradefylline blocks A2A receptors, it removes the adenosinergic brake on D2 signaling, allowing D2 agonism by pramipexole to act with less opposition and produce greater suppression of striatopallidal firing. This represents a synergistic pharmacodynamic interaction at the level of the receptor heteromer that can produce additive motor benefit beyond what either agent achieves alone. The clinical implication of this synergy is important: the same mechanism that increases motor benefit also amplifies the dopaminergic adverse effect risk. Dyskinesia can be worsened because the net motor drive is further increased; hallucinations are more likely because dopaminergic signaling is potentiated; and impulse control disorders, which are associated with both dopamine agonists and istradefylline separately, may occur with greater frequency or severity in combination. These risks do not contraindicate co-prescribing but require active monitoring. Option B correctly identifies the mechanistic synergy and its adverse effect implications.

Option A: Option A is incorrect; the two agents are not pharmacologically redundant — they act on entirely different receptor targets (A2A vs D2) and their co-administration produces synergistic rather than redundant effects; the clinical trials of istradefylline enrolled patients already on dopamine agonists and demonstrated benefit.
Option C: Option C is incorrect; there is no established mechanism by which A2A blockade upregulates D2 receptor expression requiring dose reduction of the agonist — compensatory receptor upregulation of this type is not a described pharmacological consequence of istradefylline use.
Option D: Option D is incorrect; dopamine agonist-mediated D2 agonism does not clinically downregulate A2A receptor expression to the point of eliminating istradefylline's pharmacodynamic target — the A2A receptor remains pharmacologically active and accessible in patients on agonists.
Option E: Option E is incorrect; the A2A and D2 receptors do not signal through entirely separate pathways — they share the cAMP/PKA intracellular pathway and form documented receptor heteromers with functional cross-regulation; the assertion of purely additive non-interacting effects misrepresents this established receptor pharmacology.

6. A 52-year-old woman developed drug-induced parkinsonism (DIP) after starting metoclopramide for gastroparesis. Her neurologist added benztropine for symptom control. Metoclopramide has now been successfully discontinued and her gastroparesis is being managed with dietary measures. Three months after stopping metoclopramide, her parkinsonian motor symptoms have largely resolved. How should benztropine be managed, and how does the deprescribing strategy in DIP differ from anticholinergic discontinuation in idiopathic Parkinson's disease (PD)?

A) Benztropine should be continued indefinitely because DIP, once it has occurred, indicates permanent vulnerability to cholinergic excess in the striatum; discontinuing benztropine risks re-emergence of parkinsonism even in the absence of the offending dopamine-blocking agent.
B) Benztropine should be continued at the current dose for an additional 12 months to allow complete recovery of D2 receptor sensitivity after prolonged metoclopramide blockade before attempting withdrawal.
C) Benztropine should be stopped abruptly since the underlying mechanism — D2 receptor blockade by metoclopramide — has been eliminated and there is no nigrostriatal degeneration to produce withdrawal tremor; the gradual taper required in idiopathic PD is unnecessary in DIP.
D) Benztropine should be tapered gradually in DIP just as in idiopathic PD to avoid anticholinergic withdrawal symptoms, but the taper can proceed more expeditiously because DIP is reversible — the parkinsonian motor symptoms that benztropine was controlling are resolving with metoclopramide removal, reducing the risk of clinically significant tremor rebound during the taper compared to idiopathic PD where tremor persists independently.
E) Benztropine should be switched to trihexyphenidyl before discontinuation because trihexyphenidyl's shorter duration of action produces a pharmacokinetic self-taper that minimizes withdrawal symptoms in patients whose DIP is resolving.

ANSWER: D

Rationale:

Deprescribing benztropine in this patient requires applying the general principle of anticholinergic tapering while recognizing the disease-specific difference that makes the process more straightforward in DIP than in idiopathic PD. The general principle is that anticholinergics should not be stopped abruptly after any significant period of use because withdrawal can produce a cholinergic rebound syndrome (nausea, sweating, anxiety) and because abrupt removal of muscarinic blockade that was contributing to tremor control can precipitate rebound tremor worsening. A gradual taper is therefore appropriate in DIP as well as idiopathic PD. The disease-specific difference is that DIP is mechanistically reversible: as D2 receptor blockade by metoclopramide clears and receptor sensitivity normalizes, the underlying cholinergic excess that benztropine was correcting diminishes independently. In idiopathic PD, nigrostriatal degeneration is permanent and tremor persists without intervention; in this patient with resolving DIP, the parkinsonian substrate is disappearing, substantially reducing the clinical risk of tremor rebound during the taper. This allows the taper to proceed more quickly than would be prudent in idiopathic PD. Option D correctly identifies both the shared principle (taper, not abrupt stop) and the disease-specific difference (more expeditious taper is appropriate as DIP resolves).

Option A: Option A is incorrect; DIP does not cause permanent cholinergic vulnerability — the mechanism was pharmacological D2 blockade, which is fully reversible when the offending agent is removed.
Option B: Option B is incorrect; a 12-month continuation period is not pharmacologically justified once the offending agent has been stopped and motor symptoms have largely resolved — this overstates the duration of D2 receptor recovery needed after metoclopramide discontinuation.
Option C: Option C is incorrect; even though DIP is reversible, abrupt anticholinergic discontinuation still risks cholinergic withdrawal symptoms — the taper principle applies regardless of the underlying etiology; the distinction is in the pace of taper, not whether to taper at all.
Option E: Option E is incorrect; switching to trihexyphenidyl before discontinuation does not constitute a taper and does not leverage a pharmacokinetic self-taper — trihexyphenidyl's shorter duration of action does not produce gradual dose reduction, and agent substitution delays rather than facilitates discontinuation.

7. A 66-year-old woman with Parkinson's disease (PD) is being started on Gocovri (amantadine extended-release 137 mg) for levodopa-induced dyskinesia. The pharmacist dispensing the medication notes the prescription reads "137 mg at bedtime starting night one" without a titration step. Which of the following best describes the approved titration protocol for Gocovri and the rationale for the starting dose?

A) The approved titration protocol initiates Gocovri at 68.5 mg once daily at bedtime for the first week before uptitrating to the target dose of 137 mg at bedtime; the lower starting dose reduces the incidence of early tolerability-limiting adverse effects — particularly dizziness, hallucinations, and dry mouth — that are more likely at full therapeutic exposure before the patient has had the opportunity to adapt, and allows identification of patients who may not tolerate the full dose.
B) The approved titration protocol initiates Gocovri at 137 mg at bedtime from the first night because the extended-release formulation produces a gradual rise in plasma concentrations over the first 72 hours that serves as a pharmacokinetic self-titration, making a separate lower-dose starting step unnecessary.
C) No formal titration protocol exists for Gocovri; the starting dose is at prescriber discretion based on the patient's renal function, body weight, and prior exposure to immediate-release amantadine, with 68.5 mg used for renally impaired patients and 137 mg used for all others from night one.
D) The approved titration protocol initiates Gocovri at 34 mg at bedtime for two weeks, then 68.5 mg for two weeks, then the target dose of 137 mg; this three-step protocol was required by the FDA based on the high rate of hallucinations observed at 137 mg in the EASE LID trials.
E) Gocovri is initiated at 137 mg from the first night and the dose is reduced to 68.5 mg only if tolerability-limiting adverse effects emerge within the first two weeks; this reactive dose adjustment approach is preferred over a preemptive titration step because most patients tolerate the full dose from initiation.

ANSWER: A

Rationale:

The approved prescribing information for Gocovri specifies a two-step titration: initiate at 68.5 mg once daily at bedtime for the first week, then uptitrate to the target dose of 137 mg once daily at bedtime if the lower dose is tolerated. This protocol serves an important tolerability function. The most common adverse effects of amantadine ER — including dizziness, hallucinations, dry mouth, and peripheral edema — are dose-dependent and are more likely to occur at the full 137 mg exposure if the patient has not had the opportunity to adapt at a lower concentration. The one-week step at 68.5 mg allows identification of patients who are particularly sensitive to amantadine's adverse effects, provides a lower-exposure period during which the patient can adapt, and enables informed decision-making about proceeding to the target dose. For patients with moderate renal impairment (CrCl 30–59 mL/min), 68.5 mg is not the starting dose but rather the maximum dose. Option A correctly describes the approved two-step titration and its tolerability rationale.

Option B: Option B is incorrect; while extended-release formulations do produce gradual plasma concentration rises compared to immediate-release, this pharmacokinetic property does not eliminate the clinical need for a formal titration step — the prescribing information explicitly requires the 68.5 mg starting week regardless of the extended-release profile.
Option C: Option C is incorrect; a formal titration protocol is specified in the prescribing information and is not at prescriber discretion — the 68.5 mg starting dose is not reserved for renally impaired patients but is the standard initial dose for all patients.
Option D: Option D is incorrect; the protocol is a two-step, not a three-step, titration, and the 34 mg dose does not exist in the approved dosing regimen for Gocovri.
Option E: Option E is incorrect; the approved approach is proactive titration beginning at 68.5 mg, not initiation at the full dose with reactive reduction — the prescribing information specifies the uptitration sequence, not a start-high-and-reduce approach.

8. A 70-year-old man with Parkinson's disease (PD) experiencing three hours of daily off-time on optimized levodopa therapy is about to start istradefylline 20 mg once daily. He asks his neurologist what level of improvement he should realistically expect. Which of the following best characterizes the clinical trial evidence on istradefylline's effect on off-time, and how this should inform patient counseling?

A) Clinical trials demonstrated that istradefylline eliminates off-time entirely in approximately 35 percent of patients and reduces it by more than 50 percent in an additional 40 percent; patients with three or more hours of daily off-time at baseline are most likely to achieve complete off-time elimination and should be counseled accordingly.
B) Clinical trials demonstrated that istradefylline reduces daily off-time by approximately two to three hours compared to placebo, making it comparable in magnitude to the benefit achievable with COMT inhibitors; patients with three hours of daily off-time can expect off-time to be largely eliminated with adherent use.
C) Clinical trials demonstrated that istradefylline reduces daily off-time by approximately 0.9 hours compared to placebo — a statistically significant but modest absolute reduction; patients should be counseled that istradefylline provides a real but incremental benefit and is not expected to eliminate off-time, and that this reduction may be most meaningful when added on top of already-optimized dopaminergic adjunct therapy.
D) Clinical trials demonstrated no statistically significant reduction in off-time with istradefylline compared to placebo in any individual trial; the modest pooled estimate from meta-analysis is driven entirely by one outlier study and is not considered clinically meaningful by most movement disorder specialists.
E) Clinical trials demonstrated that istradefylline's off-time reduction is dose-dependent and linear, with 20 mg reducing off-time by approximately 0.5 hours and 40 mg reducing off-time by approximately 1.5 hours; patients should be counseled to expect the larger benefit only after uptitration to the maximum dose.

ANSWER: C

Rationale:

The clinical trial evidence base for istradefylline consists of multiple phase 3 randomized controlled trials including the 6002-US-006 and 6002-US-013 studies, as well as a systematic review and meta-analysis of the istradefylline trial program. Across these trials, istradefylline consistently demonstrated a statistically significant reduction in daily off-time compared to placebo, with a pooled estimate of approximately 0.9 hours per day reduction. This is a real and clinically meaningful benefit — particularly for a patient who has already optimized dopaminergic adjunct therapy and for whom each increment of on-time represents meaningful functional gain — but it is modest in absolute terms. Patient counseling should reflect this honestly: istradefylline is not expected to eliminate off-time, and a patient with three hours of daily off-time should not expect to become off-time free. The appropriate framing is incremental benefit on top of an already-optimized regimen. Dyskinesia was not meaningfully worsened in these trials, which is an additional clinical advantage to discuss. Option C correctly characterizes the trial evidence and the appropriate counseling approach.

Option A: Option A is incorrect; istradefylline trials reported mean reductions in daily off-time rather than complete elimination rates in the proportions described — these figures are fabricated and substantially overstate the drug's effect.
Option B: Option B is incorrect; the approximate 0.9 hours per day reduction demonstrated for istradefylline is substantially less than the two to three hour figure stated, and its magnitude is not equivalent to COMT inhibitors in head-to-head comparisons — the comparison overstates the effect size.
Option D: Option D is incorrect; multiple individual istradefylline trials did demonstrate statistically significant off-time reductions, and the meta-analytic evidence is not driven by a single outlier — the evidence base supports the 0.9 hour estimate as a reproducible finding.
Option E: Option E is incorrect; the dose-response relationship between 20 mg and 40 mg is not characterized by the specific linear values stated — the prescribing information permits uptitration to 40 mg for additional benefit but does not specify a 1.5 hour reduction at the higher dose; the figures presented are fabricated.

9. A 68-year-old man with Parkinson's disease (PD) and a remote history of major depressive disorder (MDD) in full remission for eight years is being considered for Gocovri (amantadine extended-release 137 mg) for levodopa-induced dyskinesia. His neurologist recalls that the prescribing information for amantadine ER includes a warning regarding suicidal ideation. Which of the following best describes this warning and its implications for prescribing in this patient?

A) The suicidal ideation warning for amantadine ER is a black-box warning that absolutely contraindicates its use in any patient with a current or prior history of major depressive disorder, regardless of remission duration; this patient is ineligible for Gocovri.
B) The suicidal ideation warning for amantadine ER applies only to patients under age 25 based on post-marketing surveillance data; patients over age 65 are exempt from this monitoring requirement.
C) Suicidal ideation has not been reported with amantadine ER specifically; the warning in the prescribing information is a class label requirement applied to all CNS-active drugs regardless of specific signal, and no special monitoring is required in patients with a psychiatric history.
D) The suicidal ideation warning applies exclusively to the immediate-release amantadine formulation used at antiviral doses; at the lower antiparkinson doses used in Gocovri, no neuropsychiatric adverse effect risk has been established.
E) Suicidal ideation is listed as a warning in the Gocovri prescribing information based on post-marketing reports; it does not constitute an absolute contraindication but does obligate the prescriber to discuss this risk with the patient, document a baseline psychiatric assessment including current mood and suicidal ideation screening, and establish a monitoring plan — with heightened vigilance appropriate in a patient with a history of MDD even in long-term remission.

ANSWER: E

Rationale:

The prescribing information for Gocovri includes a warning for suicidal ideation and behavior based on post-marketing adverse event reports. This warning is not a black-box warning and does not constitute an absolute contraindication to use in patients with a psychiatric history; rather, it creates a prescribing obligation to proactively address the risk. The appropriate clinical response is to inform the patient of this potential adverse effect during the prescribing discussion, document a baseline assessment of current mood and screen for suicidal ideation before initiating the drug, and establish a monitoring plan for neuropsychiatric adverse effects during treatment. In a patient with a prior history of MDD — even in long-term remission — this monitoring obligation is heightened, because prior depressive episodes identify a patient with a known vulnerability to mood disorders. The history of remission does not eliminate this consideration but also does not make Gocovri contraindicated. The clinical calculus weighs the functional benefit of dyskinesia control against the monitoring burden, and in most patients with well-established remission and stable mood, Gocovri can be prescribed with appropriate safeguards. Option E correctly characterizes the warning level, the prescribing obligations, and the appropriate approach in a patient with prior MDD.

Option A: Option A is incorrect; the suicidal ideation warning is not a black-box warning and does not absolutely contraindicate use in patients with a history of MDD — characterizing it as an absolute contraindication overstates the regulatory restriction.
Option B: Option B is incorrect; there is no age threshold limiting the suicidal ideation warning to patients under 25 for amantadine ER — the age-stratified suicidal ideation warning is a feature of antidepressant labeling, not amantadine ER.
Option C: Option C is incorrect; suicidal ideation has been specifically reported with amantadine ER in post-marketing data and is not a generic class label requirement applied without a specific signal — the warning reflects a real pharmacovigilance concern.
Option D: Option D is incorrect; the distinction between antiviral doses and antiparkinson doses does not eliminate the neuropsychiatric adverse effect risk for amantadine ER — the suicidal ideation warning applies to the Gocovri formulation at its approved antiparkinson dosing.

10. A 61-year-old man with tremor-dominant Parkinson's disease (PD) has been on trihexyphenidyl 2 mg three times daily for six months with good tremor control. It is now midsummer and he asks his neurologist whether there are any special precautions he should take during hot weather while on this medication. Which of the following best explains the specific thermoregulatory risk of anticholinergic therapy and the appropriate patient counseling?

A) Anticholinergics increase the risk of hypothermia in hot weather by causing peripheral vasodilation that exceeds the body's thermoregulatory capacity; patients should be counseled to wear extra clothing and avoid air conditioning to prevent excessive heat loss.
B) Anticholinergic blockade of muscarinic receptors on eccrine sweat glands impairs sweating — the primary physiological mechanism for heat dissipation in humans — producing anhidrosis that can lead to dangerous hyperthermia during heat exposure; this patient should be counseled to avoid prolonged heat exposure, stay in air-conditioned environments during peak heat, ensure adequate hydration, and recognize early warning signs of heat illness including hot dry flushed skin, confusion, and rapid heart rate.
C) The thermoregulatory risk of anticholinergics in hot weather is confined to the first month of therapy; after six months, compensatory upregulation of beta-adrenergic sweat pathways restores normal thermoregulation and no special summer precautions are needed in established users.
D) Anticholinergics increase hyperthermia risk only when combined with other dopaminergic agents through a pharmacodynamic interaction that impairs hypothalamic thermoregulatory set-point control; since this patient is on trihexyphenidyl alone for PD, no specific heat precautions are indicated.
E) The hyperthermia risk of anticholinergics in hot weather applies only to agents with significant M2 receptor blockade affecting cardiac output; trihexyphenidyl's relative M1 selectivity in the striatum spares M2-mediated cardiovascular thermoregulatory responses, making it safer in hot weather than less selective anticholinergics.

ANSWER: B

Rationale:

Eccrine sweat glands are innervated by cholinergic sympathetic fibers and require muscarinic receptor activation — specifically M3 receptors on sweat gland epithelial cells — to secrete sweat. Anticholinergic agents block these receptors, impairing or abolishing sweating across the body surface. In hot weather, sweating is the dominant physiological mechanism for heat dissipation in humans; without it, core body temperature rises in proportion to environmental heat load and physical activity. This produces a risk of heat illness that ranges from heat exhaustion to life-threatening heat stroke. Unlike some adverse effects of anticholinergics that diminish with adaptation, anhidrosis does not resolve with prolonged use — muscarinic blockade is a pharmacodynamic effect that persists for as long as the drug is present at therapeutic concentrations. Patients on anticholinergic agents must be specifically counseled to avoid prolonged exposure to high ambient temperatures, to use air conditioning, to remain well hydrated, and to recognize the signs of heat illness including hot, dry, flushed skin (absence of sweating despite hyperthermia), confusion, and tachycardia. Option B correctly identifies the anhidrosis mechanism and provides appropriate counseling content.

Option A: Option A is incorrect; anticholinergics produce hyperthermia risk, not hypothermia — peripheral vasodilation associated with anticholinergic skin flushing is a consequence of heat retention, not a mechanism of excessive cooling.
Option C: Option C is incorrect; no compensatory upregulation of beta-adrenergic sweat pathways occurs with chronic anticholinergic use — eccrine sweating is cholinergically mediated and remains impaired for the duration of drug administration.
Option D: Option D is incorrect; the thermoregulatory risk from anticholinergic anhidrosis is a direct pharmacodynamic consequence of muscarinic sweat gland blockade and does not require co-administration of dopaminergic agents — the risk is present with trihexyphenidyl alone.
Option E: Option E is incorrect; trihexyphenidyl's anticholinergic action on sweat glands is not M1-selective — sweat gland secretion is mediated by M3 receptors, and trihexyphenidyl blocks these receptors as part of its general antimuscarinic activity; the premise of relative sweat-gland sparing based on M1 selectivity is pharmacologically inaccurate.

11. A 48-year-old woman with bipolar disorder has been on haloperidol for two years and developed drug-induced parkinsonism (DIP) for which trihexyphenidyl was added nine months ago. Her psychiatrist now switches her from haloperidol to quetiapine, which has much lower D2 receptor occupancy and minimal DIP liability. Over the following two months her parkinsonian motor symptoms fully resolve. How should trihexyphenidyl be managed, and how does the clinical reasoning differ from management of anticholinergics in idiopathic PD?

A) Trihexyphenidyl should be continued indefinitely regardless of DIP resolution because stopping it risks precipitating a permanent movement disorder; patients who have developed DIP are at lifelong risk of recurrence with any anticholinergic withdrawal.
B) Trihexyphenidyl should be continued at its current dose for at least 12 additional months to prevent latent parkinsonism from emerging as D2 receptor supersensitivity from prior haloperidol exposure wanes; premature withdrawal risks late-onset DIP recurrence.
C) Trihexyphenidyl should be stopped abruptly since the D2 receptor blockade causing DIP has been eliminated by the switch to quetiapine and the motor symptoms have resolved; the taper principle does not apply when the underlying cause of parkinsonism is pharmacological and has been removed.
D) Trihexyphenidyl should be tapered and discontinued now that the DIP has resolved — the clinical indication for continuing it no longer exists; a gradual taper over weeks to months avoids anticholinergic withdrawal symptoms and allows detection of any residual tremor, but the goal of complete discontinuation is appropriate and achievable in a way it would not be in idiopathic PD, where the underlying nigrostriatal deficit persists and tremor returns permanently without treatment.
E) Trihexyphenidyl should be reduced to the lowest dose that maintains motor stability and continued as a long-term maintenance agent because haloperidol-induced D2 receptor supersensitivity following two years of treatment creates a permanent vulnerability to cholinergic-dopaminergic imbalance that requires ongoing muscarinic blockade.

ANSWER: D

Rationale:

The clinical indication for trihexyphenidyl in this patient was DIP caused by haloperidol's D2 receptor blockade. With the switch to quetiapine and full resolution of parkinsonian motor symptoms over two months, the indication for continuing trihexyphenidyl has been eliminated. The correct management is tapering and discontinuing the drug. The key clinical reasoning distinction between DIP and idiopathic PD is one of reversibility: in idiopathic PD, nigrostriatal degeneration is permanent and the cholinergic excess that anticholinergics correct does not resolve without the drug; discontinuing anticholinergics in idiopathic PD allows tremor to return to its pre-treatment severity because the underlying deficit persists. In DIP with full motor recovery, the pathological substrate — pharmacological D2 blockade — has been removed and the striatal dopaminergic-cholinergic balance has been restored by the patient's own nigrostriatal system. Trihexyphenidyl is no longer correcting a persistent deficit; it is simply adding anticholinergic drug burden without a mechanistic justification. Complete discontinuation via a gradual taper is the goal. The taper remains appropriate to avoid cholinergic withdrawal symptoms, even though the underlying parkinsonism is resolved. Option D correctly identifies the discontinuation goal, the taper approach, and the mechanistic distinction from idiopathic PD.

Option A: Option A is incorrect; DIP is a reversible condition that does not create a lifelong risk requiring permanent anticholinergic therapy — once the offending agent is removed and motor function has normalized, the indication for continued treatment is gone.
Option B: Option B is incorrect; D2 receptor supersensitivity after haloperidol does not create a prolonged vulnerability requiring 12 additional months of anticholinergic coverage — supersensitivity is a receptor-level adaptation that normalizes over weeks to months after the blocking agent is removed, and it does not justify extended trihexyphenidyl continuation after motor recovery.
Option C: Option C is incorrect; even with resolved DIP, abrupt anticholinergic discontinuation risks cholinergic withdrawal symptoms — the taper principle applies to avoid withdrawal, even when the reason for tapering is straightforward.
Option E: Option E is incorrect; long-term maintenance trihexyphenidyl is not indicated for D2 receptor supersensitivity — supersensitivity is a transient pharmacological adaptation, not a permanent structural deficit requiring ongoing muscarinic blockade.

12. A 72-year-old man with Parkinson's disease (PD) and wearing-off has been sequentially trialed on entacapone (a catechol-O-methyltransferase [COMT] inhibitor) and rasagiline (a monoamine oxidase type B [MAO-B] inhibitor), achieving partial but inadequate off-time reduction on both agents. His neurologist considers adding istradefylline. Which of the following best describes istradefylline's mechanistic rationale in this clinical context, and how its non-dopaminergic mechanism is relevant to prescribing after dopaminergic adjuncts have been optimized?

A) Istradefylline is mechanistically appropriate in this clinical context precisely because its adenosine A2A receptor antagonism operates through an entirely different molecular pathway than entacapone's COMT inhibition or rasagiline's MAO-B inhibition — it does not increase dopamine synthesis, extend levodopa's plasma half-life, or reduce dopamine catabolism, but instead modulates indirect pathway activity to facilitate motor output; this non-dopaminergic mechanism allows it to provide additional off-time reduction without further amplifying the dopaminergic adverse effect burden already introduced by the two dopaminergic adjuncts.
B) Istradefylline is not appropriate after failed COMT and MAO-B inhibitor trials because all three agents target the same fundamental mechanism of levodopa pharmacokinetic optimization; failure of the first two agents indicates that the patient's off-time is refractory to this class of intervention and istradefylline will also fail.
C) Istradefylline should only be used as a first-line adjunct for off-time before COMT and MAO-B inhibitors are tried; using it after dopaminergic adjuncts have been initiated creates a pharmacodynamic interaction in which excessive indirect pathway suppression combined with dopaminergic augmentation produces uncontrollable dyskinesia.
D) Adding istradefylline to entacapone and rasagiline is contraindicated because istradefylline is a MAO-A inhibitor at therapeutic doses and produces a serotonin syndrome risk when combined with rasagiline's MAO-B inhibition through a shared monoamine oxidase pathway.
E) Istradefylline's off-time reduction in clinical trials was demonstrated only in patients not receiving COMT or MAO-B inhibitors; its efficacy in patients already on optimized dopaminergic adjunct therapy has not been established and its use in this setting is off-label.

ANSWER: A

Rationale:

The clinical rationale for istradefylline after dopaminergic adjunct optimization is precisely its mechanistic independence from the dopaminergic pathway. Entacapone reduces COMT-mediated levodopa catabolism, extending levodopa's plasma half-life and smoothing its concentration-time profile. Rasagiline inhibits MAO-B, reducing intraneuronal dopamine catabolism and extending the duration of dopaminergic effect. Both of these approaches work within the dopaminergic pharmacological space — they amplify or preserve dopamine signaling. When these agents have been optimized and off-time remains inadequate, adding more dopaminergic augmentation may be limited by tolerability: dyskinesia, hallucinations, orthostatic hypotension, and impulse control disorders are all dopaminergic adverse effects that can limit further dopaminergic escalation. Istradefylline operates through a non-dopaminergic pathway — A2A receptor blockade on striatopallidal neurons reduces indirect pathway overactivity and facilitates motor output without directly increasing dopamine concentrations or receptor occupancy. This mechanistic independence means it can provide additional off-time reduction without compounding the dopaminergic adverse effect burden already introduced by entacapone and rasagiline, making it a rational choice in a patient whose dopaminergic adjunct pharmacology has been optimized. Option A correctly articulates this mechanistic rationale.

Option B: Option B is incorrect; istradefylline does not share the mechanism of COMT or MAO-B inhibition — it does not target levodopa pharmacokinetics at all, and failure of dopaminergic adjuncts does not predict failure of a non-dopaminergic agent operating through an entirely different pathway.
Option C: Option C is incorrect; there is no guideline-based sequencing requirement placing istradefylline before COMT and MAO-B inhibitors, and the clinical trials for istradefylline enrolled patients on levodopa with or without other adjuncts — its use after dopaminergic optimization is both evidence-based and clinically appropriate.
Option D: Option D is incorrect; istradefylline is not a MAO-A inhibitor and has no monoamine oxidase inhibitory activity — combining it with rasagiline does not create a serotonin syndrome risk through shared monoamine oxidase pathway effects.
Option E: Option E is incorrect; the istradefylline clinical trials enrolled patients who were on levodopa and were permitted to be on other adjunct therapies including COMT and MAO-B inhibitors — the evidence base is not restricted to adjunct-naive patients.

13. A 69-year-old man with advanced Parkinson's disease (PD) is on levodopa/carbidopa, pramipexole (a dopamine D2/D3 agonist), amantadine extended-release (ER) 137 mg at bedtime for dyskinesia, and istradefylline 20 mg once daily for off-time. At a routine visit, his wife reports that over the past two months he has developed intermittent visual hallucinations in the evenings, increased interest in online gambling, and two episodes of waking confusion at night. Which of the following best describes the monitoring and management framework for this neuropsychiatric presentation in the context of this patient's polypharmacy?

A) The hallucinations are caused exclusively by istradefylline's adenosine A2A blockade producing limbic circuit disinhibition; stopping istradefylline will resolve all three neuropsychiatric findings without need to adjust the other agents.
B) The gambling behavior is caused exclusively by pramipexole's D3 receptor agonism in the mesolimbic reward pathway and is unrelated to istradefylline's own impulse control disorder warning; stopping pramipexole will resolve the impulse control disorder while amantadine ER and istradefylline can be continued unchanged.
C) All three agents in this regimen — pramipexole, amantadine ER, and istradefylline — carry recognized risks for the neuropsychiatric findings reported: dopamine agonists are strongly associated with impulse control disorders and hallucinations through mesolimbic D3 agonism; amantadine ER causes hallucinations and nighttime confusion through central NMDA antagonism and dopaminergic effects; istradefylline carries warnings for hallucinations and impulse control disorders; the clinician must systematically assess which agent is the most likely contributor to each symptom, consider reducing or stopping the agent with the weakest current clinical indication, and monitor closely while adjusting the regimen one agent at a time.
D) The nighttime confusion is caused by the pharmacokinetic interaction between amantadine ER's bedtime peak concentrations and istradefylline's once-daily morning administration; shifting istradefylline to bedtime dosing will align the two agents' peak concentrations and paradoxically reduce confusion through synchronized receptor modulation.
E) The entire neuropsychiatric syndrome represents progressive PD dementia rather than drug toxicity, since all three agents have been tolerated without incident for the preceding treatment period; no medication adjustment is indicated and the patient should be referred for neuropsychological testing to document the degree of cognitive decline.

ANSWER: C

Rationale:

This case illustrates the challenge of neuropsychiatric adverse event attribution in a patient on multiple agents that share overlapping adverse effect profiles. Each of the three adjunct agents in this regimen carries independent risk for the reported symptoms. Pramipexole, a D2/D3 receptor agonist, is strongly associated with impulse control disorders (ICDs) — including pathological gambling, hypersexuality, and compulsive shopping — through mesolimbic D3 receptor agonism, and is also associated with hallucinations through dopaminergic excess in limbic circuits. Amantadine ER causes hallucinations and nighttime confusion through its combined central NMDA antagonist and dopaminergic mechanisms; the bedtime dosing produces peak concentrations during the nighttime hours, which may be temporally associated with the waking confusion episodes. Istradefylline carries warnings for both hallucinations and impulse control disorders, and its A2A blockade with consequent indirect pathway disinhibition can contribute to neuropsychiatric symptoms. Because all three agents are plausible contributors, the correct approach is systematic rather than reflexive: assess which symptom-agent link is most pharmacologically plausible, identify which agent has the weakest current clinical indication or the best available substitute, and adjust one agent at a time to isolate the effect of each change. Stopping multiple agents simultaneously would relieve symptoms but prevent identification of the culprit, making future re-challenge or substitution decisions uninformed. Option C correctly identifies the overlapping adverse effect profiles across all three agents and prescribes a systematic one-agent-at-a-time assessment approach.

Option A: Option A is incorrect; istradefylline may contribute to hallucinations but is not the exclusive cause of all three neuropsychiatric findings — pramipexole and amantadine ER both carry independent and well-established risks for these symptoms.
Option B: Option B is incorrect; while pramipexole's D3 agonism is the most strongly established cause of ICDs in PD, istradefylline's own impulse control disorder warning makes it a plausible contributor that cannot be dismissed, and the hallucinations and nighttime confusion require assessment of all three agents, not only pramipexole.
Option D: Option D is incorrect; shifting istradefylline to bedtime is not an approved dosing strategy — istradefylline is dosed once daily at approximately the same time each day without a specific timing requirement tied to overnight peak concentrations, and synchronizing peak concentrations does not produce the therapeutic effect described.
Option E: Option E is incorrect; attributing the entire neuropsychiatric presentation to progressive PD dementia without medication review is clinically inappropriate — the onset of multiple neuropsychiatric symptoms in a patient with known exposure to three agents that all carry these risks mandates medication-focused evaluation before attributing the syndrome to disease progression.